Epidermal Growth Factor-induced Cyclooxygenase-2 Expression is Mediated Through Phosphatidylinositol-3 Kinase, Not Mitogen-activated Protein/extracellular Signal-regulated Kinase Kinase, in Recurrent Respiratory Papillomas
Overview
Affiliations
Purpose: Recurrent respiratory papillomas, caused by human papillomaviruses, are premalignant tumors that overexpress the epidermal growth factor receptor (EGFR). The goals of this study were as follows: (a) to evaluate the expression of cyclooxygenase-2 (COX-2) in papillomas, (b) to investigate the role of EGFR signaling in COX-2 expression, and (c) to determine whether COX-2 activity is important for the growth of papilloma cells.
Experimental Design: Immunohistochemistry, Western blotting, and real-time PCR were used to determine levels of COX-2 in papilloma and normal laryngeal tissue. Explant cultures of both normal laryngeal and papilloma cells were used to define the signaling pathways that regulate COX-2 expression and investigate the potential of targeting COX-2 as a strategy to suppress papilloma growth.
Results: COX-2 levels were markedly increased in papillomas. In vitro studies suggested that overexpression in papillomas reflected activation of EGFR-->phosphatidylinositol 3-kinase signaling. Treatment with prostaglandin E2 (PGE2) induced COX-2, whereas celecoxib, a selective COX-2 inhibitor, suppressed levels of COX-2, suggesting a positive feedback loop. Moreover, treatment with PGE2 stimulated papilloma cell growth, whereas celecoxib suppressed proliferation and induced apoptosis.
Conclusions: Overexpression of COX-2 in papillomas seems to be a consequence of enhanced EGFR-->phosphatidylinositol 3-kinase signaling. We propose a positive feedback loop for COX-2 expression, with induction of COX-2 resulting in enhanced PGE2 synthesis and further expression of COX-2 that contributes to the growth of papillomas in vivo. These data strengthen the rationale for evaluating whether nonsteroidal anti-inflammatory drugs, prototypic COX inhibitors, will be useful in the management of respiratory papillomas.
Preclinical Models of Laryngeal Papillomavirus Infection: A Scoping Review.
King R, Bilger A, Rademacher J, Lambert P, Thibeault S Laryngoscope. 2023; 133(12):3256-3268.
PMID: 37227124 PMC: 10674042. DOI: 10.1002/lary.30762.
DeVoti J, Israr M, Lam F, Papayannakos C, Frank D, Kamdar D Front Immunol. 2022; 13:1011772.
PMID: 36426368 PMC: 9681149. DOI: 10.3389/fimmu.2022.1011772.
Pai S, Wasserman I, Ji Y, Gilman M, Hung Y, Faquin W Lancet Respir Med. 2022; 10(10):997-1008.
PMID: 35863360 PMC: 10634185. DOI: 10.1016/S2213-2600(22)00008-X.
Two conserved amino acids differentiate the biology of high-risk and low-risk HPV E5 proteins.
Sudarshan S, Schlegel R, Liu X J Med Virol. 2022; 94(9):4565-4575.
PMID: 35509176 PMC: 9283228. DOI: 10.1002/jmv.27829.
Zarogoulidis P, Hatzibougias D, Tsakiridis K, Hohenforst-Schmidt W, Huang H, Bai C Respir Med Case Rep. 2021; 33:101398.
PMID: 33850702 PMC: 8039836. DOI: 10.1016/j.rmcr.2021.101398.